Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2013-08-08 Interim / Quarterly Rep…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Q2 Report 2013
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management Report of the First Half of 2013' and contains detailed financial results, operational performance, and management commentary for the six-month period ending June 30, 2013. It includes consolidated interim statements of operation and comparisons to the previous year. As it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2013
2013-08-08 German
Earnings Release 2013
Earnings Release Classification · 99% confidence The document text contains financial analysis, including a recommendation ('BUY'), price target, historical and estimated financial figures (Revenues, EBIT, EPS) for 2012, 2013E, and 2014E, performance data, and a financial calendar mentioning '3Q/13 Figures'. Crucially, it explicitly states the authoring entity is 'CBS Research AG' and includes a disclaimer referencing German securities law (§ 34b WpHG), indicating this is a third-party research report or investment recommendation, not an official company filing (like 10-K, ER, or IR). Since the definitions do not have a specific 'Equity Research Report' code, the closest fit for a detailed, forward-looking analysis document that is not a standard regulatory filing is 'Investor Presentation' (IP) or, given the context of financial analysis/recommendation, it often falls under a general 'Information' category. However, the structure strongly suggests a detailed analyst report providing financial forecasts and performance metrics. Given the options, 'Investor Presentation' (IP) is the best fit for a detailed, non-regulatory document summarizing performance and outlook, although 'RPA' (Report Publication Announcement) or 'RNS' (Regulatory Filings) could be considered if it were merely an announcement. Since this is the content of the analysis itself, and it contains detailed financial tables and forecasts, 'IP' (Investor Presentation) is the most appropriate classification among the choices for a detailed, non-official report. H1 2013
2013-08-08 English
Evotec to report First Half Year 2013 Results on 08 August 2013
Report Publication Announcement Classification · 99% confidence The document is a short corporate news release dated August 1, 2013, announcing that Evotec AG 'will report its financial results for the first half of 2013 on Thursday, 08 August 2013.' It provides details for an upcoming conference call and webcast. Since the document is an announcement about the future release of financial results, and not the results themselves (which would likely be an IR or ER), it fits the definition of a Report Publication Announcement (RPA). It explicitly announces the publication date of the results.
2013-08-01 English
Evotec AG: Release according to Article 26a, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly references Article 26a of the WpHG (German Securities Trading Act). It states the total number of voting rights as of a specific date (31 July 2013) and mentions an increase due to stock option exercise. This content directly relates to the official declaration of voting rights and total shares outstanding, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA). Although it is a short announcement, its specific subject matter overrides the general 'RPA' classification.
2013-07-31 English
Investor Presentation 2013
Investor Presentation Classification · 98% confidence The document is a detailed research report from 'Montega AG – Equity Research' dated July 12, 2013. It contains analyst recommendations ('Kaufen'), price targets, detailed financial tables (including forecasts for 2013e, 2014e, 2015e), performance metrics, and in-depth commentary on corporate actions (site closure, milestone payments, new collaborations). This structure is characteristic of an Investor Presentation (IP) or a detailed research report, which often accompanies or precedes formal regulatory filings. Since it provides comprehensive analysis, forecasts, and strategic commentary aimed at investors, it fits best under the 'Investor Presentation' category, which covers detailed materials for investors focusing on financials and strategy. It is not a formal regulatory filing like a 10-K or an ER, nor is it merely an announcement of a report (RPA).
2013-07-12 German
Evotec and Dow AgroSciences announce collaboration on Cellular Target Profiling
Regulatory Filings Classification · 100% confidence The document is a press release dated July 9, 2013, announcing a research collaboration between Evotec AG and Dow AgroSciences regarding Cellular Target Profiling. It contains standard press release formatting, quotes from management, 'About' sections for both companies, and a 'FORWARD LOOKING STATEMENTS' disclaimer. This type of announcement, detailing a strategic partnership or business development that is not a mandatory financial filing (like 10-K, ER, or IR), typically falls under general regulatory announcements or news releases. Since it is a specific business development announcement disseminated via a service (DGAP), and it doesn't fit the specific categories like M&A (TAR), Financing (CAP), or Earnings (ER), the most appropriate general category for non-standard regulatory news is 'Regulatory Filings' (RNS), which serves as the fallback for miscellaneous corporate news releases.
2013-07-09 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.